Verve Therapeutics to Participate in Upcoming May Investor Conferences

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the following May investor conferences:

• BofA Securities 2022 Healthcare Conference (formal presentation) on Wednesday, May 11, 2022, at 2:40 p.m. PT in Las Vegas; and,
• 2022 RBC Capital Markets Global Healthcare Conference (fireside chat) on Wednesday, May 18, 2022, at 1:35 p.m. ET in NYC.

Live webcasts will be available in the investor section of the company's website at www.vervetx.com and will be archived for 60 days following the presentations.

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby durably reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit www.VerveTx.com.

Investor ContactJen RobinsonVerve Therapeutics, Inc.[email protected]

Media ContactGina NugentTen Bridge Communications[email protected]

You May Also Be Interested In

• YieldMax® ETFs Announces Weekly Distributions for Group 2 ETFs
• Paramount Gold Announces BLM Approval of Plan of Operations and Determination of Financial Guarantee for the Grassy Mountain Project
• Robo.ai Inc. Reports More Than US$180 Million in Revenue for June-August Period